Stem cell-based therapy for neonatal lung disease: it is in the juice
Related Experiment Video
Updated: May 7, 2026

Intratracheal Instillation of Stem Cells in Term Neonatal Rats
Published on: May 4, 2020
Moses E Fung1, Bernard Thébaud2
1Women and Children's Health Research Institute, Cardiovascular Research Center and Pulmonary Research Group, University of Alberta, Edmonton, Alberta, Canada.
Insights
Bronchopulmonary dysplasia therapies are lacking. Stem cell treatments show promise for neonatal chronic lung injury by releasing therapeutic factors, not by cell engraftment.
Area of Science:
- Neonatology
- Regenerative Medicine
- Pulmonology
Background:
- Bronchopulmonary dysplasia (BPD) is the most frequent complication in extremely premature infants.
- Current clinical management lacks specific therapies for lung repair and growth in BPD.
- Stem cell biology offers potential for organ repair, shifting focus from engraftment to paracrine mechanisms.
Purpose of the Study:
- To review preclinical evidence for stem cell-based therapies in neonatal chronic lung injury.
- To explore the therapeutic potential of stem cell-derived factors for BPD treatment.
Main Methods:
- Review of preclinical studies on stem cell therapies in animal models of neonatal chronic lung injury.
- Analysis of research on paracrine mechanisms of stem cell action.
Main Results:
- Preclinical data support the therapeutic potential of cell-based approaches for neonatal lung injury.
- Stem cells appear to exert therapeutic effects primarily through secreted factors (paracrine mechanism).
Conclusions:
- Stem cell-derived factors represent a promising therapeutic avenue for bronchopulmonary dysplasia.
- Future research should focus on harnessing the paracrine effects of stem cells for BPD treatment.
Abstract:
Bronchopulmonary dysplasia, the chronic lung disease of prematurity, is the most common complication in extremely premature infants (born before 28 wk gestation). Despite advances in perinatal care, modern clinical management remains devoid of therapies specifically promoting lung repair and lung growth. Recent progress in stem cell biology has uncovered the promise of stem/progenitor cells to repair damaged organs. Contrary to the original theory that stem cells engraft and repopulate the damaged organ, evidence suggests that stem cells act via a paracrine mechanism. This review highlights the preclinical evidence for the therapeutic potential of cell-based therapies in animal models of neonatal chronic lung injury and the multiple therapeutic avenues offered by soluble stem cell-derived factors.
More Related Videos
Related Concept Videos
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
iPS Cell Differentiation
Stem Cell Culture
Adult Stem Cells

